ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in...

Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today announced the launch of KYMBEE™ (deflazacort) Oral Suspension, 22.75 mg/mL...

Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. announced that it completed more than 200 customer audits and...

Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to...

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Bortezomib for Injection in the United...

WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), announced the successful...

Rugiet, the performance medicine company that’s helped more than 500,000 men take control of their health, announced the expansion of its treatment areas to include...

Bayer announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for...

The EVERY Company ("EVERY"), a leader in highly functional egg proteins produced via precision fermentation, announced a significant manufacturing expansion with its strategic partner, Huvepharma, a...

Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting...

AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was...